The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q.
The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may increase their doses to 100 mg after FDA’s approval.
It can happen in 3Q 2023, increasing CPRX's quarterly and annual revenues by $3.5 million and $14 million, respectively.
I calculate that each new FIRDAPSE customer, on average, can increase CPRX’s annual revenue by more than $0.28 million.
More patients in the United States and Canada are expected to start taking FIRDAPSE. Also, by 2Q 2024, patients in Japan might start taking FIRDAPSE.
>>1
The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q.
The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may increase their doses to 100 mg after FDA’s approval.
It can happen in 3Q 2023, increasing CPRX's quarterly and annual revenues by $3.5 million and $14 million, respectively.
I calculate that each new FIRDAPSE customer, on average, can increase CPRX’s annual revenue by more than $0.28 million.
More patients in the United States and Canada are expected to start taking FIRDAPSE. Also, by 2Q 2024, patients in Japan might start taking FIRDAPSE.
希少疾患だから、2024年の第２四半期に日本で投与開始されたところで、劇的に利益が上がるのかな？
あとは、訴訟がうまく決着してくれれば、また元の株価に戻ると期待してます。